X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (73) 73
Conference Proceeding (9) 9
Publication (8) 8
Book Review (3) 3
Book Chapter (1) 1
Dissertation (1) 1
Patent (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (36) 36
oncology (36) 36
humans (33) 33
melanoma (27) 27
female (25) 25
male (24) 24
middle aged (24) 24
melanoma - drug therapy (22) 22
aged (20) 20
ipilimumab (20) 20
adult (17) 17
survival (16) 16
melanoma - pathology (14) 14
aged, 80 and over (13) 13
immunotherapy (13) 13
metastasis (13) 13
patients (13) 13
cancer (12) 12
pembrolizumab (12) 12
melanoma - mortality (11) 11
tumors (11) 11
mutation (10) 10
clinical trials (9) 9
metastatic melanoma (9) 9
skin neoplasms - drug therapy (9) 9
antibodies, monoclonal, humanized - therapeutic use (8) 8
care and treatment (8) 8
chemotherapy (8) 8
research (8) 8
treatment outcome (8) 8
abridged index medicus (7) 7
antibodies, monoclonal, humanized - adverse effects (7) 7
pd-1 protein (7) 7
skin neoplasms - mortality (7) 7
skin neoplasms - pathology (7) 7
therapy (7) 7
adolescent (6) 6
analysis (6) 6
antineoplastic agents - therapeutic use (6) 6
antineoplastic agents, immunological - therapeutic use (6) 6
article (6) 6
disease-free survival (6) 6
drug therapy (6) 6
medical research (6) 6
melanoma - genetics (6) 6
melanoma - metabolism (6) 6
melanoma - secondary (6) 6
neoplasm staging (6) 6
protein kinase inhibitors - therapeutic use (6) 6
proto-oncogene proteins b-raf - antagonists & inhibitors (6) 6
proto-oncogene proteins b-raf - genetics (6) 6
safety (6) 6
antibodies, monoclonal - adverse effects (5) 5
antibodies, monoclonal - therapeutic use (5) 5
antineoplastic agents, immunological - adverse effects (5) 5
antineoplastic combined chemotherapy protocols - therapeutic use (5) 5
cancer therapies (5) 5
cell lung-cancer (5) 5
confidence intervals (5) 5
dosage and administration (5) 5
dose-response relationship, drug (5) 5
drug administration schedule (5) 5
drug therapy, combination (5) 5
ipilimumab - adverse effects (5) 5
ipilimumab - therapeutic use (5) 5
nivolumab (5) 5
patient outcomes (5) 5
retrospective studies (5) 5
trial (5) 5
young adult (5) 5
antineoplastic agents - adverse effects (4) 4
blockade (4) 4
braf (4) 4
complications and side effects (4) 4
expression (4) 4
health aspects (4) 4
immune checkpoint (4) 4
ligands (4) 4
malignant-melanoma (4) 4
medicine, experimental (4) 4
medicine, general & internal (4) 4
metastases (4) 4
mitogen-activated protein kinase kinases - antagonists & inhibitors (4) 4
neoplasm metastasis (4) 4
prognosis (4) 4
skin cancer (4) 4
skin neoplasms - genetics (4) 4
survival rate (4) 4
toxicity (4) 4
antibodies, monoclonal - administration & dosage (3) 3
antibodies, monoclonal, humanized - administration & dosage (3) 3
antimitotic agents (3) 3
antineoplastic agents (3) 3
antineoplastic agents - pharmacology (3) 3
antineoplastic combined chemotherapy protocols - adverse effects (3) 3
antitumor activity (3) 3
apoptosis (3) 3
biomarkers (3) 3
cell death (3) 3
combined nivolumab (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 06/2015, Volume 372, Issue 26, pp. 2521 - 2532
Journal Article
The Lancet, ISSN 0140-6736, 10/2017, Volume 390, Issue 10105, pp. 1853 - 1862
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2012, Volume 367, Issue 18, pp. 1694 - 1703
The combination of a BRAF inhibitor (dabrafenib) and a MEK inhibitor (trametinib) in patients with metastatic melanoma produced a significantly higher response... 
CELL LUNG-CANCER | METASTATIC MELANOMA | MEDICINE, GENERAL & INTERNAL | EFFICACY | PATHWAY | SAFETY | KINASE | RESISTANCE | DOSE-ESCALATION TRIAL | RAF INHIBITORS | IMPROVED SURVIVAL | Oximes - pharmacokinetics | Oximes - adverse effects | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Oximes - therapeutic use | Male | Imidazoles - pharmacokinetics | Fever - chemically induced | Drug Therapy, Combination - adverse effects | Melanoma - genetics | Adult | Female | Imidazoles - therapeutic use | Pyridones - pharmacokinetics | Imidazoles - adverse effects | Pyrimidinones - adverse effects | Pyrimidinones - therapeutic use | Mitogen-Activated Protein Kinase Kinases - antagonists & inhibitors | Melanoma - secondary | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Disease-Free Survival | MAP Kinase Signaling System - drug effects | Pyrimidinones - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Aged | Pyridones - therapeutic use | Mutation | Pyridones - adverse effects | Drugs | Dose-response relationship (Biochemistry) | Usage | Patient outcomes | Melanoma | Product/Service Evaluations | Research | Antineoplastic agents | Antimitotic agents | Gene mutations | Causes of | Genetic aspects | Dosage and administration | Drug therapy, Combination | Drug therapy | Cell survival | Protein kinase | Skin diseases | MAP kinase | Kinases | Patients | Drug dosages | Fever | Metastases | Index Medicus | Abridged Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 05/2018, Volume 378, Issue 19, pp. 1789 - 1801
A blinded trial involving patients with resected stage III melanoma showed that adjuvant pembrolizumab every 3 weeks for a year was associated with a 1-year... 
HIGH-RISK MELANOMA | SURVIVAL | MEDICINE, GENERAL & INTERNAL | ANTI-PD-1 THERAPY | EORTC 18952 | TUMOR BURDEN | CUTANEOUS MELANOMA | PHASE-3 TRIAL | PEGYLATED INTERFERON-ALPHA-2B | NODE-POSITIVE MELANOMA | IPILIMUMAB | Skin Neoplasms - drug therapy | Humans | Middle Aged | Male | Adjuvants, Immunologic - adverse effects | Skin Neoplasms - mortality | Aged, 80 and over | Adult | Female | Adjuvants, Immunologic - therapeutic use | Skin Neoplasms - surgery | Antibodies, Monoclonal, Humanized - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Double-Blind Method | Kaplan-Meier Estimate | Neoplasm Recurrence, Local | Survival Rate | Disease-Free Survival | B7-H1 Antigen - antagonists & inhibitors | Melanoma - drug therapy | Intention to Treat Analysis | Quality of Life | Aged | B7-H1 Antigen - analysis | Infusions, Intravenous | Melanoma - surgery | Neoplasm Staging | Melanoma - mortality | Diagnosis | Drug therapy | Patients | Health aspects | Melanoma | Medical research | Lymphatic system | Risk groups | PD-1 protein | Committees | Metastasis | Survival | Skin cancer | Pembrolizumab | Hospitals | Motivation | PD-L1 protein | Myositis | Death | Mutation | Tumors | Cancer | Index Medicus | Abridged Index Medicus | Placebos | Placebos (Medicine) | Adjuvant treatment of cancer | Tractament adjuvant del càncer
Journal Article
Science, ISSN 0036-8075, 10/2018, Volume 362, Issue 6411, pp. 197 - 197
Programmed cell death protein-1 (PD-1) and programmed cell death ligand-1 (PD-L1) checkpoint blockade immunotherapy elicits durable antitumor effects in... 
CELL LUNG-CANCER | MISMATCH-REPAIR DEFICIENCY | MUTATIONAL PROCESSES | METASTATIC MELANOMA | CTLA-4 BLOCKADE | MULTIDISCIPLINARY SCIENCES | COPY NUMBER | PROGRAMMED DEATH LIGAND-1 | SEQUENCING DATA | CLINICAL-RESPONSE | SOMATIC MUTATIONS | Antibodies, Monoclonal, Humanized - therapeutic use | Humans | Transcriptome | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Genetic Markers | Cell Cycle Checkpoints | Neoplasms - therapy | Neoplasms - genetics | Antineoplastic Agents, Immunological - therapeutic use | Immunotherapy | Inflammation - genetics | T-Lymphocytes - immunology | Tumor Burden - genetics | Biomarkers, Tumor - genetics | Mutation | Molecular Targeted Therapy - methods | Monoclonal antibodies | Genetic aspects | T cells | Biological markers | Gene expression | Cancer | Tumors | Apoptosis | Cell receptors | Physiological aspects | Diagnosis | Identification and classification | Methods | PD-1 protein | Clinical trials | Genomes | Biology | Lymphocytes T | Microsatellite instability | Data bases | Subgroups | Anticancer properties | Proteins | Cell activation | Pembrolizumab | Databases | Antigenicity | Lymphocytes | Bioindicators | Deoxyribonucleic acid--DNA | Medical research | Stability | Microsatellites | Mortality | Melanoma | Data processing | Inflammation | Patients | Immune checkpoint | Cell death | Correlation analysis | PD-L1 protein | Biomarkers | Ligands | Antitumor activity | Cutoffs | Solid tumors | Index Medicus
Journal Article
Journal Article
The lancet. Diabetes & endocrinology, ISSN 2213-8587, 11/2013, Volume 1, Issue 3, pp. e15 - e15
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 1/2015, Volume 75, Issue 1, pp. 183 - 189
To identify the maximum tolerated dose (MTD) and recommended Phase II dose of MEK/AKT inhibitor combination of trametinib and afuresertib.Eligibility criteria... 
Medicine & Public Health | MEK Inhibitor | Afuresertib | Oncology | Cancer Research | Pharmacology/Toxicology | Combination therapy | AKT Inhibitor | Trametinib | MEK inhibitor | AKT inhibitor | MELANOMA | ONCOLOGY | PATHWAY | MUTATION | PHARMACOLOGY & PHARMACY | HUMAN CANCER | Thiophenes - therapeutic use | Pyrazoles - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Thiophenes - adverse effects | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Antineoplastic Agents - therapeutic use | Thiophenes - administration & dosage | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Dose-Response Relationship, Drug | Early Termination of Clinical Trials | Pyridones - administration & dosage | Multiple Myeloma - drug therapy | Neoplasms - blood | Antineoplastic Agents - adverse effects | Adult | Female | Antineoplastic Agents - pharmacokinetics | Multiple Myeloma - enzymology | Pyrazoles - pharmacokinetics | Multiple Myeloma - blood | Pyrazoles - adverse effects | Protein Kinase Inhibitors - pharmacokinetics | MAP Kinase Kinase 1 - antagonists & inhibitors | Pyridones - pharmacokinetics | Pyrimidinones - adverse effects | Pyrimidinones - therapeutic use | Neoplasms - enzymology | Neoplasms - drug therapy | Protein Kinase Inhibitors - administration & dosage | Thiophenes - pharmacokinetics | Pyrazoles - administration & dosage | Pyrimidinones - pharmacokinetics | Tumor Burden - drug effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | MAP Kinase Kinase 2 - antagonists & inhibitors | Protein Kinase Inhibitors - therapeutic use | Aged | Pyridones - therapeutic use | Pyrimidinones - administration & dosage | Proto-Oncogene Proteins c-akt - antagonists & inhibitors | Pyridones - adverse effects | Cohort Studies | Complications and side effects | Medical research | Care and treatment | Type 1 diabetes | Analysis | Gastrointestinal diseases | Multiple myeloma | Melanoma | Medicine, Experimental | Aspartate | Nausea | Tumors | Index Medicus
Journal Article
European Journal of Cancer, ISSN 0959-8049, 11/2017, Volume 86, pp. 37 - 45
Journal Article